27/02/2026
XTL Biopharmaceuticals Ltd. (the “Company”) issued a press release announcing that the Company has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)
READ MORE >>

24/02/2026
The Company announces the results of the Extraordinary General Meeting held on Tuesday, February 24, 2026, in Tel Aviv, Israel.
READ MORE >>

23/01/2026
The Social Proxy Ltd., an Israeli company and wholly owned subsidiary of the Company (the “Social Proxy”), has filed a formal application with the competent Israeli court for the commencement of insolvency proceedings
READ MORE >>

13/01/2026
XTL Biopharmaceuticals Enters Binding LOI to Acquire NeuroNOS in Strategic Transaction with Beyond Air
READ MORE >>

13/01/2026
XTL Biopharmaceuticals Announces Extraordinary General Meeting of Shareholders
READ MORE >>